Abstract Purpose:To examine the prognostic significance of expression of glutathione s-transferase k (GST-k) and p53 in patients treated with radiation alone for locally advanced head and neck cancer [Radiation Therapy Oncology Group (RTOG), trial 9003] or radiation F concomitant chemotherapy as postoperative adjuvant therapy (RTOG trial 9501). Experimental Design: Immunohistochemical staining for p53 and GST-k was done on tissue samples from 393 patients in RTOG 9003 and 142 patients in RTOG 9501. Kaplan-Meier survival analyses were done. Results: Patients who had low expression of both markers had longer survival than patients who had high expression of both markers. In trial 9003, median survival was 2.4 years for patients with low expression of both markers versus 1.4 years for patients who had elevated expression of both markers (P = 0.07). These differences were highly significant in trial 9501and were accounted for by the chemotherapy treated arm. In this group, patients with low expression of both markers had a median survival of 7.0 years compared with 1.4 years for patients with elevated expression of both markers (P = 0.006). In both trials, black patients had lower survival rates than did white patients and there was a trend toward higher expression of both markers in blacks compared with whites.
Squamous cell cancer of the head and neck remains a major public health problem in the United States and world wide. More than 44,000 cases were estimated in the United States in 2007 with >11,000 deaths (1) . Concomitant platinum-based chemoradiotherapy has emerged as the standard of care for many patients with locally advanced head and neck cancer both for organ preservation and as adjuvant therapy for patients with resectable high risk disease (2) .
A number of studies have evaluated biochemical and molecular markers as predictive and/or prognostic indicators in head and neck cancer (3 -7) . Most of these analyses have been done retrospectively on small data sets, and few investigators have validated their retrospective findings in independent data sets. No consensus has emerged about clinically practical markers, which may be used to stratify risk or guide therapy.
Numerous studies have evaluated the prognostic significance of p53 in head and neck cancer and other malignancies (8 -10) . Immunohistochemical detection of mutated p53 in most but not all of these studies has been associated with poor prognosis.
Our own laboratory has developed several lines of evidence that phase II enzymes in the glutathione pathway may have an important role in mediating resistance to cisplatin-based chemotherapy regimens (11) . Elevation of intracellular glutathione levels or increased expression of the conjugating enzyme glutathione S-transferase k (GST-k) is associated with an increased ability of the cell to resist reactive oxygen species damage induced by cisplatin (12) . Our previous study on retrospective data collected from 68 patients suggested that over expression of GST-k had strong negative prognostic value in patients receiving neoadjuvant cisplatin-based chemotherapy for locally advanced head and neck cancer. Overall survival at 3 years was 82% for patients with low GST-k expression compared with 46% for patients with elevated GST-k (P = 0.0018). p53 expression was also a strong negative prognostic indicator and was independent of GST-k expression. Overall survival at 3 years was 81% in the p53 low patients but only 30% in the p53 high group (P < 0.0001; ref. 13) . Whereas these studies focused on the role of GST-k and p53 in patients treated with cisplatin-based chemotherapy regimens, the broader function of GST-k in the cellular response to reactive oxygen species and the function of mutated p53 in regulation of apoptosis suggests that these markers may have a lesser but meaningful prognostic significance in patients treated with radiation as well (14) .
In this study, we analyzed expression of p53 and GST-k in samples from two Radiation Therapy Oncology Group (RTOG) randomized clinical trials. Trial 9003 was a four-arm trial looking at differing fractionation schedules for radiotherapy as primary treatment. This study of radiation alone in locally advanced tumors showed accelerated fractionation with concomitant boost and hyperfractionation schedules were associated with improved local regional control but not a significant improvement in survival compared with standard fractionation. RTOG trial 9501 was a randomized trial of conventional fraction radiotherapy versus radiotherapy given with concomitant cisplatin (100 mg/m 2 on days 1, 22, and 43) as postoperative adjuvant therapy for resectable high risk head and neck cancer patients (15) . In that trial, concurrent chemotherapy and radiotherapy significantly improved local control and disease-free survival compared with radiation alone.
Based on our previous work, we hypothesized that patients with low expression of GST-k and p53 would have a favorable prognosis in these studies, whereas patients with high expression of both factors would have a poor prognosis and that this effect would be more pronounced in patients receiving chemotherapy compared with those receiving radiation alone. This study was undertaken to validate our previous findings in an independent data set.
As a secondary and exploratory analysis, we examined survival as well as expression of p53 and GST-k by race in the two studies.
Experimental Design
Study populations. RTOG studies 9003 and 9501 were selected for analysis because pretreatment biopsy specimens for many of the patients on those trials were available through the RTOG tissue bank.
RTOG 9003 randomized 1,113 patients with locally advanced head and neck cancer to 4 radiotherapy fractionation schedules. Patients (1,073) were evaluable for outcome. Of these, 393 had staining results for both markers and complete clinical data available through the RTOG tissue bank. RTOG 9501 randomized 459 resected patients with locally advanced head and neck cancer to receive adjuvant radiotherapy or adjuvant radiotherapy with concomitant cisplatin. Of these, 142 patients had tissue available through the RTOG tumor bank. For each trial, tissue microarrays were assembled by the RTOG tissue bank, which included multiple punches (triplicate or quadruplicate) of each pretreatment biopsy.
Immunohistochemistry. Immunohistochemistry for p53 and GST-k was done as previously described (11), except monoclonal antibody clone 353 to 10 (Dako North America) was used for GST-k.
Sample scoring. Samples were scored by a pathologist (N.N.) who had no knowledge of, or access to, clinical outcome data. Samples were scored for the percentage of tumor cells, which showed positive staining as well as the intensity of staining per the published protocol of Allred (16) . For subsequent statistical analysis, intensity scores below the median were considered low and scores above the median were considered high.
Statistical analysis. Included in the analysis are 535 patients who had adequate specimen for the biomarker assays from a total 1,572 patients in these two trials. The medians of the two biomarkers (GST-k and p53) in these patients are used as the cut points to group patients as the low (L) and high (H) expression groups. Hence, there were four categories of patients, i.e., LL, LH, HL, and HH. Overall survival was defined as the length of time from the date of randomization to death from any cause. The overall survival was estimated using the Kaplan-Meier method, and the log-rank test was used to compare survival distribution among/between different patient groups. The Cox regression model was used to assess significance of multiple factors such as biomarkers, patient clinical and demographic characteristics, and protocols. Associations between categorical variables were assessed using a Fisher's exact or Fisher-Freeman-Halton test. All statistical tests were done at the two-sided 0.05 level of significance.
Results
Baseline pretreatment patient characteristics in this report (those with tumor specimens) are similar to those of the entire patient population in each of the two trials. (Table 1) .
Formal statistical tests (n = 10) comparing analyzed (those with tissue samples) and excluded (those without tissue samples) for each characteristic in each trial were done. The
Translational Relevance
A number of studies have evaluated biochemical and molecular markers as predictive and/or prognostic indicators in head and neck cancer. Most of these analyses have been done retrospectively on small data sets, and few investigators have validated their retrospective findings in independent data sets. No consensus has emerged about clinically practical markers that may be used to stratify risk or guide therapy.
In this study of Radiation Therapy Oncology Group trials 9003 and 9501, we expand on previous work from our group and show that elevated expression of glutathione S-transferase k and mutated p53 confer poor prognosis in patients receiving adjuvant treatment for head and neck cancer. These markers have greatest predictive value in patients receiving concomitant cisplatin and radiation and less in patients receiving radiation alone. Patients with low or absent expression of these markers are likely to benefit from concomitant cisplatin and radiation in the adjuvant setting.
This study also shows a disquieting disparity with black patients showing a significantly poorer outcome compared with whites. The data suggest that some of this disparity may be attributed to elevated expression of these adverse markers in blacks.
unadjusted P values for all the characteristics in each trial are greater than as previously described (9) . Except for treatment assigned in RTOG 9003, which has a P value of 0.03. However, this difference (see Table 1 ) is not practically significant and with multiple comparisons (9), the difference is in fact not statistically significant using the Bonferroni correction.
The Cox model suggests that there is no interaction between the four biomarker groups and protocols (P = 0.09). The survival distribution is significantly different among the four biomarker groups (P = 0.004, stratified by the two RTOG protocols). The survival benefit in RTOG 9501 is significantly greater than that in RTOG 9003 (P = 0.02). The analysis for each specific protocol was then done and is summarized in Tables 1 to 3 and Figs. 1 to 3. RTOG 9003. Figure 1 shows the survival curves for the 393 patients with available tumor biopsies based on expression of GST-k and p53. The four subgroups (p53 and GST-k low, p53 high and GST-k low, p53 low and GST-k high, and p53 high and GST-k high) had different survival experiences (marginal statistical significance, P = 0.07, log-rank test). As expected, patients who had low expression of both markers had better survival than patients who had elevated expression of both markers. Median survival was 2.4 years [95% confidence interval (95% CI), 1.4-3.0 years] for patients with both markers low versus 1.3 years (95% CI, 1.0-1.9 years) for patients with both markers high. Five-year survival was 35% for patients for patients with low expression of both markers compared with 22% for patients with high expression of both markers. Multivariable Cox regression model adjusted for patients' demographic and clinical characteristics including age (P = 0.11), gender (P = 0.72), kps (P < 0.0001), primary tumor site (P = 0.05), T stage (P = 0.03), and N stage (P = 0.0002) revealed that these 2 biomarkers continued to have statistically significant effect on overall survival (P = 0.04).
RTOG 9501. Figure 2A shows the survival curves for patients on trial 9501 (n = 142) based on expression of GST-k and p53. In this trial, expression of the markers was highly significant with regression analysis showing a highly Research.
on August 29, 2017. © 2008 American Association for Cancer clincancerres.aacrjournals.org Downloaded from significant adverse survival difference based on marker expression (P = 0.02). Patients with low expression of both markers had a median survival of 6.8 years (the lower bound of the 95% CI is 1.9 years, the upper has not been reached yet) compared with 1.5 years (95% CI, 1.1-2.9 years) for patients with high expression of both markers (P = 0.005). Five-year survival was 54% for patients with low expression of both markers compared with 24% for patients with elevated expression of both markers.
Further analysis of trial 9501 showed that the survival difference predicted by the markers was accounted for almost exclusively by the patients in the combined chemotherapy/ radiation arm. Figure 2B shows the survival analysis for patients who received chemotherapy and radiation. In this group, median survival time for patients with low expression of both markers has not been reached yet (the lower boundary of the 95% CI is 2.5 years), and was 1.4 years (95% CI, 1.0-2.9 years) for patients high for both markers. This difference in overall survival was highly statistically significant, P = 0.006 (log-rank test). Five-year survival was 60% for patients with low expression of both markers versus 16% for patients with elevated expression of both markers. Multivariable Cox regression model adjusted for patients' demographic and clinical characteristics including age (P = 0.11), gender (P = 0.72), kps (P < 0.0001), primary tumor site (P = 0.05), T stage (P = 0.03), and N stage (P = 0.0002) revealed that these two biomarkers continued to have statistically significant effect on overall survival (P = 0.04).
In contrast, the markers were not predictive in the radiation alone arm of trial 9501. Figure 2C shows survival curves for the radiation arm in that study. Marker expression was not associated with differences in survival (P = 0.54).
Racial disparities analysis. Of the 393 complete samples available for analysis from RTOG 9003, 78 (20%) were from blacks, whereas 286 (73%) were from whites. In study RTOG 9501, of the 142 specimens available, 33 (23%) were from blacks and 101 (71%) were from whites. This significant percentage of participation by black patients prompted a preliminary analysis of survival and marker expression in the two racial groups. In trial 9003, for patients with available biopsy material, median survival was 2.1 years (95% CI, 1.7-2.7 years) for white patients versus 1.3 years (95% CI, 1.1-1.9 years) for blacks. Five-year survival was 32% for whites versus 21% for blacks (P = 0.011; Fig. 3A ).
For patients with available biopsy tissue in trial 9501, blacks similarly fared less well than whites. Median survival was 4.3 years (95% CI, 2.2-4.7 years) for whites versus 2.2 years (95% CI, 1.3-3.2 years) for blacks. Five-year survival was 47% for whites versus 23% for blacks. (Fig. 3B) . Because of the smaller sample size in trial 9501, the P value for the log-rank test comparing overall survival is of marginal significance (P = 0.053), but the magnitude of racial difference is similar in both trials. Black patients in trial 9003 had significantly higher N stage at presentation than white patients with a trend toward higher T stage (Table 2) . In trial 9501, there was no statistical difference in T stage or N stage between black and white patients (Table 3) likely reflecting the relatively small number (n = 33) of blacks with available tumor biopsies in that trial.
An exploratory analysis of marker expression in black and white patients showed a trend toward elevated expression in blacks, which approached but did not reach statistical significance. In trial 9003, the median score for both GST-k and p53 was higher in blacks versus whites. For GST-k, median score was 2.0 among blacks versus 1.5 for whites (P = 0.19). For p53, the median score was 2.0 for blacks versus 1.75 for whites (P = 0.06). In trial 9003, of 286 white patients, 107 (37%) scored low for both markers, whereas among black patients, 22 of 78 (28%) scored low for both markers (P = 0.14). Eighteen percent of white patients expressed high levels of both markers, whereas for blacks, 27% scored high for both (P = 0.08).
In trial 9501, no significant differences in expression of GSTk or p53 were seen comparing blacks to whites, possibly because of the relatively small number of black patients (33) available for analysis from that trial.
Discussion
Cisplatin-based chemo/radiatiotherapy has become the standard of care both for locally advanced unresectable head and neck cancer, to facilitate organ preservation and for adjuvant therapy of postoperative patients at high risk for recurrence. However, a significant portion of patients recur with either local or distant disease that is generally fatal. Attempts to identify biomarkers of prognosis that would improve upon clinical variables including tumor-node-metastasis staging have been limited. To date, no biomarkers have been accepted for routine clinical use. Most of the available literature consists of retrospective single institution studies that have not been validated in independent sample sets, particularly in a clinical trial setting. The current study attempted to validate a previous retrospective analysis in two independent data sets, RTOG clinical trials 9003 and 9501. Our previous two institution retrospective study showed significant negative prognostic value for both p53 and GST-k in patients receiving neoadjuvant chemotherapy for locally advanced head and neck cancer. Based on that analysis, we predicted that elevated expression of these two markers would be a negative prognostic indicator in patients undergoing combined chemotherapy and concomitant chemotherapy and radiation. Because of the broad roles of p53 and GST-k in cellular damage response, we predicted that these markers would have a lesser significance in patients receiving radiation alone. The current study shows that both of these hypotheses were correct. Analysis of available biopsy tissues from RTOG 9003 showed that patients with expression of both p53 and GST-k did worse than patients who did not express either marker; this difference approached statistical significance. In contrast, results from trial 9501 showed a significant difference in survival between patients who expressed both markers and patients who expressed neither marker. These differences were largely accounted for by patients who had been randomized to the chemotherapy/radiation arm as patients who received radiation alone showed no statistical differences based on biomarker expression.
The current findings suggest that a readily completed immunohistochemical marker analysis may have important prognostic significance for patients undergoing cisplatin-based combined chemoradiotherapy for locally advanced head and neck cancer. Given the poor outcome of chemoradiotherapy treatment patients with elevated expression of both p53 and GST-k, these patients may not be appropriate candidates for organ preservation based on standard protocols and may be better managed with primary surgery or considered for clinical trials with alternative radiation sensitizing regimens. Conversely, patients with low expression of both markers seem to be good candidates for combined chemoradiotherapy.
It is important to note that the chemoradiotherapy arm of trial 9501 was in the postoperative adjuvant setting. Although we hypothesize that similar outcomes would be seen in an examination of patients receiving cisplatin-based chemoradiotherapy as primary treatment of advanced disease, the data presented here do not establish that with certainty. Unfortunately, the RTOG tissue bank does not contain such a clinical sample set.
The current study findings also provide disquieting new data regarding the racial disparities in head and neck cancer and hint that biochemical differences in the tumors may explain some of the differences in outcome between black and white patients. In both trials 9003 and 9501, black patients fared worse than did white patients. The poor survival for black patients approached significance in trial 9501 and was highly significant in trial 9003. Trial 9003 had a sufficient sample size to facilitate the preliminary analysis of marker expression by race. In that study, black patients had a trend for higher expression of both p53 and GST-k, which approached statistical significance. The semiquantitative immunohistochemical scheme used in this analysis has the benefit of simplicity but makes it difficult to quantify small differences in expression in small groups of patients. We have previously shown that overexpression of GST-k measured by immunohistochemistry is frequently associated with increased gene Fig. 2 . RTOG 9501: survival curves estimated by the Kaplan-Meier method. In this trial of adjuvant radiotherapy randomized with concomitant chemo-radiotherapy, patients with low expression of both markers had significantly improved survival compared with patients with elevated expression of one or both markers (A , all 142 patients, P = 0.02). In the combined chemotherapy arm (B), expression of one or both markers correlated negatively with survival (P = 0.06). Patients with high expression of both markers had a median survival of 1.5 y, whereas for patients with low expression of both markers, median survival had not been reached. (P = 0.006). Analysis of the radiation alone cohort showed no significant difference in survival based on marker expression. (C, P = 0.54).
copy number measured by fluorescence in situ hybridization (17) . More precise quantitative assessment of GST-k may be possible with that methodology.
Of note, black patients in 9003 presented with higher N stage and a trend toward higher T stage than white patients in the same study. We cannot make firm conclusions about whether the adverse survival seen is due to delay in time to diagnosis or whether elevated expression of p53 or GST-k in and of themselves are associated with more aggressive tumor behavior resulting in more advanced stage at diagnosis.
The biological bases of differences in outcome for blacks and whites remain largely undefined, especially in head and neck cancer. The National Cancer Institute Black/White Cancer Survival Study examined colon, breast, uterine, and bladder tumors and showed poorer survival for black patients in all those diseases after adjustment for both clinical and socioeconomic characteristics (18, 19) . These findings gave credence to the concept that some cancers may be biologically more aggressive in blacks compared with whites. However, a more recent metaanalysis of survival from clinical studies reported for 14 tumor types including head and neck showed decreased survival for blacks only for breast, uterine, and bladder cancer. The authors conclude that disparities in survival for other tumors including head and neck are accounted for principally by differences in treatment, stage at presentation, and mortality from other conditions (20) . Several studies have recently analyzed national data from the Surveillance, Epidemiology and End Results database. These analyses of oral and pharyngeal cancer consistently show that blacks present with more advanced disease than whites and that the age-adjusted mortality rate for these cancers is nearly twice as high for blacks compared with whites (21, 22) . One recent analysis of the same Surveillance, Epidemiology and End Results data suggests that even correcting for stage at diagnosis, blacks had significantly worse survival than whites (23) . A single institution retrospective study confirmed that disease specific mortality was significantly higher for blacks than whites after adjusting for other factors including tumor-node-metastasis stage. Intensity of treatment was similar for both groups and did not account for the differences in survival (24) .
The current study was not designed or powered to address these issues definitively, but does show a trend toward increased expression of these two adverse markers in black patients and suggests that further attention to this issue is warranted.
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